Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, 119435 Moscow, Russia.
Department of Abdominal Surgery and Oncology II (Coloproctology and Uro-Gynecology), Petrovsky National Research Center of Surgery, 119435 Moscow, Russia.
Cells. 2024 Aug 27;13(17):1437. doi: 10.3390/cells13171437.
The gut microbiota plays an essential role in maintaining immune homeostasis and influencing the immune landscape within the tumor microenvironment. This review aims to elucidate the interactions between gut microbiota and tumor immune dynamics, with a focus on colorectal cancer (CRC). The review spans foundational concepts of immuno-microbial interplay, factors influencing microbiome composition, and evidence linking gut microbiota to cancer immunotherapy outcomes. Gut microbiota modulates anti-cancer immunity through several mechanisms, including enhancement of immune surveillance and modulation of inflammatory responses. Specific microbial species and their metabolic byproducts can significantly influence the efficacy of cancer immunotherapies. Furthermore, microbial diversity within the gut microbiota correlates with clinical outcomes in CRC, suggesting potential as a valuable biomarker for predicting response to immunotherapy. Conclusions: Understanding the relationship between gut microbiota and tumor immune responses offers potential for novel therapeutic strategies and biomarker development. The gut microbiota not only influences the natural history and treatment response of CRC but also serves as a critical modulator of immune homeostasis and anti-cancer activity. Further exploration into the microbiome's role could enhance the effectiveness of existing treatments and guide the development of new therapeutic modalities.
肠道微生物群在维持免疫稳态和影响肿瘤微环境中的免疫景观方面发挥着重要作用。本综述旨在阐明肠道微生物群与肿瘤免疫动态之间的相互作用,重点关注结直肠癌(CRC)。该综述涵盖了免疫微生物相互作用的基础概念、影响微生物组组成的因素以及将肠道微生物群与癌症免疫治疗结果联系起来的证据。肠道微生物群通过几种机制调节抗癌免疫,包括增强免疫监测和调节炎症反应。特定的微生物物种及其代谢产物可以显著影响癌症免疫治疗的疗效。此外,肠道微生物群中的微生物多样性与 CRC 的临床结果相关,表明其作为预测免疫治疗反应的有价值的生物标志物的潜力。结论:了解肠道微生物群与肿瘤免疫反应之间的关系为新型治疗策略和生物标志物的开发提供了机会。肠道微生物群不仅影响 CRC 的自然史和治疗反应,而且还作为免疫稳态和抗癌活性的关键调节剂。进一步探索微生物组的作用可以提高现有治疗方法的效果,并指导新的治疗方式的发展。
Int Immunopharmacol. 2024-8-20
Biomed Pharmacother. 2023-9
Int Rev Immunol. 2024
Turk J Gastroenterol. 2024-11-28
Biomolecules. 2025-7-14
Int J Mol Sci. 2025-4-15
Braz J Otorhinolaryngol. 2025-4-29
Nat Rev Cancer. 2024-7
Front Immunol. 2024
Gastroenterol Rep (Oxf). 2024-2-16